254 related articles for article (PubMed ID: 25487560)
1. Olanzapine-induced weight gain plays a key role in the potential cardiovascular risk: evidence from heart rate variability analysis.
Wang J; Liu YS; Zhu WX; Zhang FQ; Zhou ZH
Sci Rep; 2014 Dec; 4():7394. PubMed ID: 25487560
[TBL] [Abstract][Full Text] [Related]
2. Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder.
Andersen SW; Clemow DB; Corya SA
J Clin Psychiatry; 2005 Nov; 66(11):1468-76. PubMed ID: 16420086
[TBL] [Abstract][Full Text] [Related]
3. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.
Citrome L; Holt RI; Walker DJ; Hoffmann VP
Clin Drug Investig; 2011; 31(7):455-82. PubMed ID: 21495734
[TBL] [Abstract][Full Text] [Related]
4. Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia.
Bishop JR; Ellingrod VL; Moline J; Miller D
Med Sci Monit; 2006 Feb; 12(2):BR47-50. PubMed ID: 16449941
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid type 1 receptor gene polymorphisms are not associated with olanzapine-induced weight gain.
Park YM; Choi JE; Kang SG; Koo SH; Kim L; Geum D; Lee HJ
Hum Psychopharmacol; 2011; 26(4-5):332-7. PubMed ID: 21695734
[TBL] [Abstract][Full Text] [Related]
6. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study.
Ujike H; Nomura A; Morita Y; Morio A; Okahisa Y; Kotaka T; Kodama M; Ishihara T; Kuroda S
J Clin Psychiatry; 2008 Sep; 69(9):1416-22. PubMed ID: 19193342
[TBL] [Abstract][Full Text] [Related]
7. Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database.
Bushe CJ; Slooff CJ; Haddad PM; Karagianis JL
J Psychopharmacol; 2013 Apr; 27(4):358-65. PubMed ID: 23343595
[TBL] [Abstract][Full Text] [Related]
8. Heart rate variability during sleep in patients with schizophrenia treated with olanzapine.
Mann K; Rossbach W; Müller MJ; Müller-Siecheneder F; Ru H; Dittmann RW
Int Clin Psychopharmacol; 2004 Nov; 19(6):325-30. PubMed ID: 15486517
[TBL] [Abstract][Full Text] [Related]
9. [Antipsychotics--clever choices].
Ek M; Lindefors N
Lakartidningen; 2007 Feb 14-20; 104(7):504-8. PubMed ID: 17375681
[No Abstract] [Full Text] [Related]
10. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
Saddichha S; Ameen S; Akhtar S
J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
[TBL] [Abstract][Full Text] [Related]
11. Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial.
Bhowmick S; Hazra A; Ghosh M
Aust N Z J Psychiatry; 2010 Mar; 44(3):237-42. PubMed ID: 20050717
[TBL] [Abstract][Full Text] [Related]
12. Influence of olanzapine on QT variability and complexity measures of heart rate in patients with schizophrenia.
Bär KJ; Koschke M; Berger S; Schulz S; Tancer M; Voss A; Yeragani VK
J Clin Psychopharmacol; 2008 Dec; 28(6):694-8. PubMed ID: 19011440
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
Mukundan A; Faulkner G; Cohn T; Remington G
Cochrane Database Syst Rev; 2010 Dec; (12):CD006629. PubMed ID: 21154372
[TBL] [Abstract][Full Text] [Related]
14. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
Lee SY; Park MH; Patkar AA; Pae CU
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):490-6. PubMed ID: 21146575
[TBL] [Abstract][Full Text] [Related]
15. [Olanzapine--high potency antipsychotic drug inducing significant weight gain: a case report].
Marić N; Josifović-Kostić D; Vuković O; Britivić D; Jasović-Gasić M
Srp Arh Celok Lek; 2008; 136(5-6):284-8. PubMed ID: 18792627
[TBL] [Abstract][Full Text] [Related]
16. Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.
Kemp DE; Correll CU; Tohen M; Delbello MP; Ganocy SJ; Findling RL; Chang K
J Child Adolesc Psychopharmacol; 2013 Oct; 23(8):522-30. PubMed ID: 24111982
[TBL] [Abstract][Full Text] [Related]
17. The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients.
Poyurovsky M; Pashinian A; Levi A; Weizman R; Weizman A
Int Clin Psychopharmacol; 2005 Mar; 20(2):101-3. PubMed ID: 15729086
[TBL] [Abstract][Full Text] [Related]
18. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.
Poyurovsky M; Pashinian A; Gil-Ad I; Maayan R; Schneidman M; Fuchs C; Weizman A
Am J Psychiatry; 2002 Jun; 159(6):1058-60. PubMed ID: 12042201
[TBL] [Abstract][Full Text] [Related]
19. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study.
Poyurovsky M; Fuchs C; Pashinian A; Levi A; Faragian S; Maayan R; Gil-Ad I
Psychopharmacology (Berl); 2007 Jun; 192(3):441-8. PubMed ID: 17310385
[TBL] [Abstract][Full Text] [Related]
20. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
